1. Home
  2. LYEL vs IMXI Comparison

LYEL vs IMXI Comparison

Compare LYEL & IMXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$17.35

Market Cap

401.8M

Sector

Health Care

ML Signal

HOLD

Logo International Money Express Inc.

IMXI

International Money Express Inc.

HOLD

Current Price

$15.21

Market Cap

469.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
IMXI
Founded
2018
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
401.8M
469.3M
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
LYEL
IMXI
Price
$17.35
$15.21
Analyst Decision
Strong Buy
Buy
Analyst Count
5
2
Target Price
$30.60
$15.00
AVG Volume (30 Days)
51.8K
734.8K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
$36,000.00
$319,601,000.00
Revenue This Year
N/A
$0.83
Revenue Next Year
$8,712.13
$1.49
P/E Ratio
N/A
$762.00
Revenue Growth
N/A
16.68
52 Week Low
$0.40
$8.58
52 Week High
$45.00
$15.95

Technical Indicators

Market Signals
Indicator
LYEL
IMXI
Relative Strength Index (RSI) 36.48 27.70
Support Level $17.34 $14.87
Resistance Level $19.02 $15.53
Average True Range (ATR) 1.22 0.20
MACD -0.21 -0.06
Stochastic Oscillator 34.78 32.55

Price Performance

Historical Comparison
LYEL
IMXI

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About IMXI International Money Express Inc.

International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

Share on Social Networks: